Stock BAVA BAVARIAN NORDIC A/S
Add to a list
To use this feature you must be a member
Log inSign up

Bavarian Nordic A/S Stock

Equities

BAVA

DK0015998017

Pharmaceuticals

Real-time Estimate Cboe Europe
Other stock markets
 05:14:08 2024-12-12 am EST 		5-day change 1st Jan Change
200.20 DKK +0.05% Intraday chart for Bavarian Nordic A/S +4.13% +12.99%
Dec. 11 Bavarian Nordic Plans DKK150 Million Share Repurchase MT
Dec. 11 Bavarian Nordic to buy back shares for up to DKK 150 million FW

Valuation: Bavarian Nordic A/S

Capitalization 15.72B 2.21B 2.11B 1.95B 1.73B 3.13B 187B 3.47B 24.29B 8.99B 77.08B 8.3B 8.12B 337B P/E ratio 2024 *
17x
P/E ratio 2025 * 7.7x
Enterprise value 14.42B 2.03B 1.93B 1.79B 1.59B 2.87B 172B 3.19B 22.29B 8.25B 70.74B 7.62B 7.45B 309B EV / Sales 2024 *
2.55x
EV / Sales 2025 * 1.73x
Free-Float
98.02%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data

Chart: Bavarian Nordic A/S

Dynamic Chart

Latest news: Bavarian Nordic A/S

Bavarian Nordic Plans DKK150 Million Share Repurchase Dec. 11 MT
Bavarian Nordic to buy back shares for up to DKK 150 million Dec. 11 FW
New mpox vaccines for Congo's children held up by old problem Nov. 26 RE
Bavarian's CEO: Sales will not be affected with Kennedy as Health Secretary - Børsen Nov. 19 FW
Carnegie Group Upgrades Bavarian Nordic to Buy, Lifts PT Nov. 18 MT
Danske Bank lowers target price for Bavarian Nordic to DKK 370 (375), reiterates Buy - BN Nov. 18 FW
Carnegie raises Bavarian Nordic to buy (hold), target price DKK 245 - BN Nov. 18 FW
Health Care Down as RFK Fears Mount -- Health Care Roundup Nov. 15 DJ
Bavarian Nordic A/S, Q3 2024 Earnings Call, Nov 15, 2024 Nov. 15
US expected to increase biodefence spending under Trump, says vaccine maker Bavarian Nordic Nov. 15 RE
European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department Nov. 15 DJ
Europe's STOXX 600 opens lower as tech, healthcare shares drag Nov. 15 RE
Bavarian Nordic has $340 million orders for its mpox, smallpox vaccine in 2025 Nov. 15 RE
More news

Last Transcript: Bavarian Nordic A/S

Logo Bavarian Nordic A/S
Bavarian Nordic A/S, Q3 2024 Earnings Call, Nov 15, 2024
Nov. 15
More transcripts

Analysts' recommendations: Bavarian Nordic A/S

Carnegie Group Upgrades Bavarian Nordic to Buy, Lifts PT Nov. 18 MT
Danske Bank lowers target price for Bavarian Nordic to DKK 370 (375), reiterates Buy - BN Nov. 18 FW
Carnegie raises Bavarian Nordic to buy (hold), target price DKK 245 - BN Nov. 18 FW
Today's stock recommendations at a glance Oct. 02 FW
Carnegie raises target price for Bavarian Nordic to DKK 238 (230), reiterates Hold - BN Oct. 02 FW
More recommendations

Press Releases: Bavarian Nordic A/S

Bavarian Nordic to Launch DKK 150 Million Share Buy-back Program Dec. 11 GL
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise Dec. 02 AQ
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such Nov. 29 GL
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such Nov. 29 AQ
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise Nov. 29 GL
More press releases

News in other languages: Bavarian Nordic A/S

Nvid-IA Day Nov. 20
En Direct des Marchés : STMicro décale ses objectifs, plans sociaux chez Teleperformance et ArcelorMittal Nov. 20
Leichter - Kennedy-Schock für Pharmaaktien Nov. 15
Etwas leichter - Applied Materials belastet Chipaktien Nov. 15
Produttori vaccini Ue deboli su nomina Kennedy Jr a segretario Salute Usa Nov. 15
More news

Quotes and Performance

1 day+3.06%
1 week+4.33%
Current month+3.46%
1 month-4.07%
3 months-14.96%
6 months+16.24%
Current year+12.76%
More quotes

Course Extremes

1 week
190.05
Extreme 190.05
205.00
1 month
166.30
Extreme 166.3
205.10
Current year
143.40
Extreme 143.4
300.00
1 year
143.40
Extreme 143.4
300.00
3 years
115.20
Extreme 115.2
411.00
5 years
103.20
Extreme 103.2
411.00
10 years
103.20
Extreme 103.2
444.00
More quotes

Managers and Directors: Bavarian Nordic A/S

Director TitleAgeSince
Paul Chaplin CEO
 Chief Executive Officer 57 2014-05-27
Henrik Juuel DFI
 Director of Finance/CFO 59 2018-10-31
Russell Thirsk COO
 Chief Operating Officer 56 2022-03-31
Manager TitleAgeSince
Anders Gersel Pedersen BRD
 Director/Board Member 73 2010-04-26
Frank Verwiel BRD
 Director/Board Member 61 2016-04-19
Anne Eberhard BRD
 Director/Board Member 61 2019-04-23
More insiders

ETFs: Bavarian Nordic A/S

Name Weight AuM 1st Jan change Investor Rating
SIMPLIFY DEVELOPED EX-US PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Developed Ex-US Plus Downside Convexity ETF - USD
0.01% 10 M€ -3.35% -
More ETFs: Bavarian Nordic A/S

Other Pharmaceuticals

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
BAVARIAN NORDIC A/S Stock Bavarian Nordic A/S
+3.06%+4.33%+17.53%-26.38%2.21B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
-0.44%-4.07%+36.30%+226.05%717B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+1.00%+1.32%+18.10%+110.47%492B
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.74%-2.55%-5.43%-11.39%353B
ABBVIE INC. Stock AbbVie Inc.
-0.74%-1.18%+15.29%+38.97%308B
MERCK & CO., INC. Stock Merck & Co., Inc.
-1.24%-1.60%-4.43%+37.36%252B
ROCHE HOLDING AG Stock Roche Holding AG
+0.83%+0.87%+0.63%-32.12%232B
ASTRAZENECA PLC Stock AstraZeneca PLC
+0.25%+0.55%+4.38%+28.62%208B
NOVARTIS AG Stock Novartis AG
-0.92%-2.40%+2.76%+17.79%199B
AMGEN INC. Stock Amgen Inc.
-0.85%-1.74%+0.47%+29.65%147B
Average +0.18%-0.57%+8.56%+41.90% 291.08B
Weighted average by Cap. -0.06%-1.45%+13.16%+82.49%
See all sector performances

Financials

2024 *2025 *
Net sales 5.66B 796M 759M 704M 624M 1.13B 67.47B 1.25B 8.74B 3.24B 27.74B 2.99B 2.92B 121B 7.32B 1.03B 982M 910M 807M 1.46B 87.27B 1.62B 11.31B 4.19B 35.89B 3.87B 3.78B 157B
Net income 936M 132M 126M 116M 103M 186M 11.16B 207M 1.45B 535M 4.59B 494M 483M 20.07B 2.06B 290M 276M 256M 227M 410M 24.56B 455M 3.18B 1.18B 10.1B 1.09B 1.06B 44.17B
Net Debt -1.29B -182M -173M -161M -143M -257M -15.42B -286M -2B -740M -6.34B -683M -668M -27.73B -3.07B -432M -412M -382M -339M -611M -36.65B -679M -4.75B -1.76B -15.07B -1.62B -1.59B -65.91B
More financial data * Estimated data

Company Profile

Logo Bavarian Nordic A/S
Bavarian Nordic A/S specializes in the development, manufacturing and commercialization of cancer immunotherapies and vaccines for the prevention and treatment of infectious diseases. Net sales by revenue source are divided between sales of products (97.8%) and services (2.2%). Net sales are distributed geographically as follows: the United States (36.5%), Canada (22%), France (10.5%), Germany (10.1%), Spain (6.1%), Australia (4.8%), Switzerland ( 1.5%), Sweden (1%), Chile (0.9%), Taiwan (0.8%), the United Kingdom (0.6%), Hong Kong (0.2%), Saudi Arabia (0.1%), and others (4.9%).
Employees
1,609
Sector
Pharmaceuticals
Calendar
2025-03-04 - Q4 2024 Earnings Release
More about the company

Quotes

Date Price Change Volume
24-12-12 200.40 kr +0.15% 88,896
24-12-11 200.10 kr +3.06% 522,453
24-12-10 194.15 kr -1.04% 224,896
24-12-09 196.20 kr +0.28% 149,356
24-12-06 195.65 kr +1.61% 233,341

Delayed Quote Nasdaq Copenhagen, December 11, 2024 at 11:20 am EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart BAVARIAN-NORDIC-A-S More financial data

Ratings

Trading Rating
Investor Rating
ESG Refinitiv
B
surperformance-ratings-light-chart BAVARIAN-NORDIC-A-SMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
200.10DKK
Average target price
319.50DKK
Spread / Average Target
+59.67%
Consensus
Profit revisions
estimates-change-chart BAVARIAN-NORDIC-A-S Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart BAVARIAN-NORDIC-A-S Company calendar
  1. Stock Market
  2. Equities
  3. BAVA Stock